Zolbetuximab with chemotherapy for untreated claudin 18.2-positive HER2 negative unresectable advanced gastric or gastro-oesophageal junction adenocarcinoma [ID5123] Draft guidance Technology ...
NICE has recommended belzutifan for some adults with Von Hippel-Lindau disease, in final draft guidance, which could benefit ...
This summary report is based on the NICE assumptions used in the resource impact template. Users can amend the 'Inputs and eligible population' and 'Unit costs' worksheets in the template to reflect ...
The 4 technology appraisal committees are standing advisory committees of NICE. This topic was considered by committee C. Committee members are asked to declare any interests in the technology being ...
Futibatinib (Lytgobi, Taiho) is indicated for 'the treatment of adult patients with locally advanced or metastatic cholangiocarcinoma with a fibroblast growth factor receptor 2 (FGFR2) fusion or ...
This summary report is based on the NICE assumptions used in the resource impact template. Users can amend the 'inputs and eligible population' and 'unit costs' worksheets in the template to reflect ...
The evaluation committee considered evidence submitted by Taiho, a review of this submission by the external assessment group (EAG), and responses from stakeholders. See the committee papers for full ...
The 4 technology appraisal committees are standing advisory committees of NICE. This topic was considered by committee C. Committee members are asked to declare any interests in the technology being ...
Faricimab (Vabysmo) is available on the NHS. It is a possible treatment for visual impairment caused by macular oedema after central or branch retinal vein occlusion in adults Is this treatment right ...
10395 - Aprocitentan for treating resistant hypertension TS ID 10395 Technology appraisal guidance Abatacept for treating active idiopathic inflammatory myopathies TS ID 10095 Technology appraisal ...
This topic was evaluated as a single technology evaluation by the highly specialised technologies evaluation committee. Because of this, some members of the technology evaluation committees were ...
NICE has recommended evinacumab alongside diet and other low-density lipoprotein-cholesterol (LDL‑C) lowering therapies, within its marketing authorisation, as an option for treating homozygous ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results